Drug Target Review – Issue 2 2020
Posted: 26 May 2020 | Drug Target Review | 1 comment
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
This issue includes:
- SCREENING
High-throughput screening as a method for discovering new drugs
Matthew Lloyd, University of Bath - ANTIBODIES
Antibodies against viral disease: highlighting technologies behind COVID-19 antibody therapy
Shalom Gurjar, OXGENE - IMMUNO-ONCOLOGY
Neoantigens: presenting new vaccine opportunities in immuno-oncology
Nikki Withers, Drug Target Review - IMAGING
Data, data and still more data: the challenges of imaging and analysing 3D cell models
Margaritha Mysior, University College Dublin
Jeremy Simpson, University College Dublin - STEM CELLS
Application of organoid technology for retinal disease modelling and drug discovery
Valeria Chichagova, Newcastle University and Newcells Biotech
The rest of this content is restricted - login or subscribe free to access
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Antibodies, Drug Development, Drug Discovery, Drug Targets, Genomics, High Throughput Screening (HTS), Imaging, Immuno-oncology therapeutics, Research & Development, Stem Cells
Related organisations
Molecular Devices
Very informative article..